Tag Archives: International Research

Early Signs of a Historic Breakthrough in the Treatment of Alzheimer’s Disease? (BBC News / Nature)

Posted on September 1, 2016 by Dementia and Elderly Care News

Summary Early results, based on small numbers of patients in a Phase I trial, indicate unprecedented progress in the development of a pharmacological treatment of Alzheimer’s Disease. The drug Aducanumab appears to combat (and reverse) the build-up of amyloid protein … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Scotland, UK, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, BBC Health News, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Butler Hospital (USA), Centre for Cognitive and Neural Systems at the University of Edinburgh, Clinical Dementia Rating—Sum of Boxes, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Identification of People At Risk of Dementia, Institute for Regenerative Medicine: University of Zurich, International Collaborations, International Programmes, International Research, Intravenous Infusions of Aducanumab, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Mini Mental State Examination (MMSE), Monoclonal Antibodies, Neurimmune (Switzerland), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurofibrillary Tangles, Positron Emission Tomography (PET), Research and Development, Research and Innovation, Research Commitment, Slowing of Cognitive Decline, Susceptibility to Side-Effects of Medication, Switzerland, Treatment of Alzheimer's Disease, University College London, University of Edinburgh, University of Zurich | Leave a comment

New Drugs for Dementia (POST Note PN 535)

Posted on August 29, 2016 by Dementia and Elderly Care News

Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program | Leave a comment

Developments in Dementia Research: From the Horses’ Mouths (NHS England / NIHR)

Posted on August 25, 2016 by Dementia and Elderly Care News

Summary Professor Alistair Burns (NHS England’s National Clinical Director for Dementia and Older Peoples’ Mental Health), and Professor Martin Rossor (NIHR National Director for Dementia Research), discuss current issues and new approaches in dementia research, touching briefly upon some of … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Models of Dementia Care, National, NHS England, NIHR, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged 100000 Genomes Project, A4 Study, Alistair Burns: Honorary Consultant Old Age Psychiatrist in the Manchester Mental Health and Social Care Trust (MMHSCT), Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alzheimer's Prevention Initiative, Alzheimer’s Disease Biomarkers, Alzheimer’s Prevention Initiative Study, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study), APP and Presenilin, Asymptomatic Alzheimer’s Disease, Banner Alzheimer's Institute, Biomarkers, Chance Genetic Mutations, Colombia, Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, DIAN-TU Study, DIAN-TU Trial, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Genentech, Genomics, Genomics England, Genomics in the NHS, Genomics-Based Medicine, Global Outlook, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Medellin (Colombia), Monoclonal Antibodies, MRC Neurochemical Pharmacology Unit, Mutational Signatures, National Clinical Director for Dementia, National Institute for Health Research (NIHR), National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, NIHR Clinical Research Network, NIHR Dementia Translational Research Collaboration, NIHR National Director for Dementia Research, NIHR Translational Research Collaboration, Overcoming Barriers, Participation in Research, Participation in Research Studies, Preclinical Alzheimer's Disease, Presenilin, Prodromal Alzheimer's Disease, Professor Alistair Burns, Professor Martin Rossor: Director of the NIHR Queen Square Dementia Biomedical Research Unit, Professor Martin Rossor: Former Director of the NIHR Dementia and Neurodegenerative Disease Research Network (DeNDRoN), Professor Martin Rossor: Former President of the Association of British Neurologists (2011-2013), Professor Martin Rossor: Honorary Consultant Neurologist at National Hospital for Neurology and Neurosurgery, Professor Martin Rossor: National Hospital (Queen Square), Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Martin Rossor: UCL Institute of Neurology, Promisary Science, Reducing Downstream Effects of Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Solanezumab (Sola or Solab), Solanezumab: Humanised Monoclonal Antibody, Therapeutic Nihilism (Avoiding), Translational Research, UK Genomes Project: Genomics England, University of Southern California’s Alzheimer’s Therapeutic Research Institute, Washington University School of Medicine | Leave a comment

Google’s “Moonshot Project” on Tackling Ageing (Financial Times / Reuters / BBC News / ICO / Health and Technology / HTN)

Posted on September 5, 2014 by Dementia and Elderly Care News

Summary Arthur Levinson, formerly of Genentech, has left Roche to avoid any potential conflict of interest in his role as chief executive of Google’s Calico start-up company. Calico recently agreed a $1.5bn alliance with AbbVie, a rival of Roche, to develop treatments for … Continue reading →

Posted in Assistive Technology, In the News, International, Management of Condition, Non-Pharmacological Treatments, Parkinson's Disease, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged 23andMe, AbbVie, Acute Kidney Injury (AKI), Age and Ageing, Age-Related Disease Research, Age-Related Neurodegenerative and Neurovascular Diseases, Ageing and Dementia, Ageing and Society, Ageing Population, Ageing Well, AI for Good Programme (Microsoft), AI for Health Programme (Microsoft), Arthur Levinson, Artificial Intelligence, Artificial Intelligence (AI), Attitudes to Ageing, Basline Study: Collection of Anonymous Genetic and Molecular Information, BBC Health News, Big Data, Big Pharma, BRAC, Compensation for Shaky Hands (Assistive Technology), Data Protection Act (1998), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Information Sharing), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Partnership Working), Data Sharing, Data Sharing Agreement, Data Sharing for Better Health, DeepMind Health, Diffusion of Innovation, Disease-Detecting Nanoparticles, Economist (Journal), Elizabeth Denham, Elizabeth Denham: Information Commissioner, Encouraging Innovation, Essential Tremor, Faculty of Law and Computer Laboratory: University of Cambridge, Financial Times, Fred Hutchinson Cancer Research Center (Seattle), FT.com, Genentech, Google, Google Ageing-Related Ambitions, Google Basline Study: Anonymous Genetic and Molecular Information, Google Health-Related Ambitions, Google Moonshot Projects, Google Moonshot Projects: Ageing-Related, Google X, Google X: Cutting-Edge Technology Projects, Google X: Potentially Revolutionary Innovation, Google's DeepMind, Google's Research Division: Google X, Google's Social Network: Google+, Google’s Calico, Google’s DeepMind and Royal Free Trust Data-Sharing Agreement, Google’s Health Portfolio, Health and Technology (Journal), Health Technology, Healthy Life Expectancy, HTN: Health Tech Newspaper, Human Longevity, Information Commissioner’s Office (ICO), Information Commissioner’s Website, Intelligent Retinal Imaging Systems (IRIS), International Collaborations, International Dementia Research Inventories, International Programmes, International Research, Lift Labs, Longevity, Novartis Foundation, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Data and Big Data, Open Science, Open Source Solutions, Partnership and Collaboration, Partnership Working, PATH, Pharmaceutical Industry, Pharmacological Research, Policies on Ageing, Preventative Care, Proactive Care, Reinventing Ageing, Research and Innovation, Reuters, Roche, Royal Free Hospital (London), Royal Free London NHS Trust, Royal Free NHS Foundation Trust, Science of Ageing, Seattle Children’s Research Institute, Smart Contact Lenses, Stabilization Technology: Tremor Cancellation, Streams app (Google’s DeepMind), Supporting Healthy Lifestyles, Tremor, Tremor and Other Hyperkinetic Movements, Tremor Cancellation Spoon (Stabilization Technology), Tremor-Cancelling Devices | Leave a comment

French Alzheimer Plan (2008-2012): Quick Evaluation (Lancet / JAD / ADI)

Posted on May 27, 2014 by Dementia and Elderly Care News

Summary A short Lancet article assesses the impact of the French Alzheimer Plan (2008-2012). Government funding and coordination was provided by the Ministry of Health, the Alzheimer Foundation Plan and the French National Research Agency. A bibliometric analysis, summarised in … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Non-Pharmacological Treatments | Tagged 2008-2012 French Alzheimer Plan, Alzheimer Foundation Plan, Alzheimer's Research, Building Research Capacity, Centres for Early-Onset Alzheimer Disease, CHU de Nice, CIMA: Corpus Minimum d'information Alzheimer), CMRR – EA CoBTeK-CHU, Cross-National Research, Département de Santé Publique: Nice, Département des Maladies Chroniques et des Traumatismes (Saint-Maurice: France), Dementia Research, Dementia Research Priorities, Ellipse (Ste Anastasie sur Issole: France), European Alzheimer's Disease Initiative (EADI), France, French Alzheimer Information System, French Alzheimer Plan (2008-2012), French Alzheimer Plan (2008-2012): 44 Measures on Alzheimer’s Disease and Related Disorders, French National Alzheimer Databank (BNA), French National Research Agency, Genetic Research, Government Research Funding, Institut de Veille Sanitaire, International Collaborations, International Programmes, International Research, JAD, Kappa Santé (Paris), Lancet, Lille, Medical Research, MEMENTO, Memory Centers, Memory Resource and Research Centers, Memory Units, Ministry of Health (France), National Alzheimer Data Bank (Nice: France), National Alzheimer Information System (France), Neuroimaging of Dementia, Paris, Research Programmes, Rouen, Système d'Interrogation de Gestion et d'Analyse des Publications Scientifiques (SIGAPS), Three Cities, Université de Nice (Sophia Antipolis), Université Lille 2 | Leave a comment

Annual Progress Report(s) on Prime Minister’s Dementia Challenge (Department of Health / Dementia Challenge)

Posted on May 9, 2014 by Dementia and Elderly Care News

Summary The three Dementia Challenge Champion Groups have written brief reports detailing their progress during the past year. These reports feature in a letter to the Prime Minister (see below), which also reiterates achievements since the Prime Minister’s Dementia Challenge … Continue reading →

Department of Health Met US Congressional Delegation About Dementia Challenge (Department of Health / Dementia Challenge)

Posted on March 25, 2014 by Dementia and Elderly Care News

Summary A Congressional Delegation from the United States visited the Department of Health on March 17th 2014, focusing on dementia. The aim was to develop further ways in which US and UK policymakers and healthcare leaders might work together on meeting the challenges of dementia and … Continue reading →

Posted in Department of Health, In the News, International, Models of Dementia Care, National, Quick Insights, UK, Universal Interest | Tagged Age and Ageing, Ageing and Dementia, Ageing and Society, Ageing Population, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Congressional Delegation (US), Congressmen, Congresswomen, Data Sharing, Dementia Challenge, Dementia Friendly Communities Programme, Dementia Research, Diagnosis Rates, First G8 Dementia Summit, Former Health Secretary Jeremy Hunt, G8 Dementia Summit, G8 Dementia Summit Agreements, Global Action Against Dementia, Global Context, Global Outlook, Government Research Funding, Information Sharing, International Action Plan for Research, International Collaborations, International Programmes, International Research, Liberal Democrat MP Norman Lamb: Former Health Minister (Coalition Government), Living Well with Dementia, Multicampus Program in Geriatrics Medicine and Gerontology, Norman Lamb MP (Former Minister of State for Care and Support), Prime Minister’s Dementia Challenge, Research and Innovation, Research Commitment, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Science and Innovation, UCLA: Center for Health Sciences, United States, University of California, USA, USAgainst Alzheimer’s African American Network Against Alzheimer’s | Leave a comment

Tag Archives: International Research

Early Signs of a Historic Breakthrough in the Treatment of Alzheimer’s Disease? (BBC News / Nature)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites